K. N. von Kaulla

Urinary Procoagulant Excretion and its Relation to Kidney Function

A powerful procoagulant is normally excreted in large amounts in the urine of man, rats and rabbits. The secretion is not altered in a variety of diseases including hemorrhagic diathesis and thromboembolism. In parenchymatous kidney diseases, however, there is a marked reduction of procoagulant excretion. The procoagulant excretion is negatively correlated with BUN, blood creatinine and degree of proteinuria. With marked proteinuria in human or experimental renal disease, the procoagulant content per ml urine and the 24 h excretion drop to very low or zero values. In man, complete recovery of procoagulant excretion is obtained after homotransplantation of a well functioning kidney.

Synthetic activators of fibrinolysis which possess anticoagulant property.

Derivate von Salicylsäure aktivieren im Reagenzglas das fibrinolytische System des menschlichen Plasmas und üben eine gerinnungshemmende Wirkung aus. Durch planmässige Veränderungen der Substituenten des Salicylsäuremoleküls gelang es, in zunehmendem Masse Verbindungen mit steigender fibrinolytischer Aktivität aufzufinden. Die gerinnungshemmende und fibrinolytische Wirkung wird am Beispiel derortho-Thymotinsäure erläutert.

Reduced excretion of urinary procoagulant in uremic patients

Ein hochaktiver, gerinnungsfördernder Faktor wird normalerweise im menschlichen Urin ausgeschieden. Die Ausscheidung ist quantitativ bei gesunden Erwachsenen altersabhängig und bei Urämie wesentlich vermindert.

Prevention of dog serum-induced aggregation of pig platelets.

Summary Dog serum-induced aggregation of pig platelets in plasma has been considered to be an in vitro model for xenograft rejection. In this paper it is shown that this aggregation can be reduced or totally prevented by pretreatment of the dog serum with certain synthetic fibrinolytic agents or pentosane polysulfo esters or by adding the latter to pig plasma. The common denominator of these compounds is their complement suppressing activity.

Extraction of Plasminogen Activator from Canine Vascular Segments in Situ

Summary Plasminogen activator is easily recovered from canine veins in situ by solutions retained in vessel lumens, previously emptied of blood. The veins can be extracted repeatedly before they become exhausted. A pH of 5, low ion strength, and the presence of digitonon will enhance the plasminogen activator release. Low temperatures will block it. The external jugular vein generally yielded more plasminogen than did the femoral vein. The femoral artery yielded very little activator.